https://www.onhealthcare.tech/p/royalty-pharma-for-real-world-dataThoughts on Healthcare Markets & Technologyen2026-07-15T13:28:24+00:00Royalty Pharma for Real World Data: The Case for a Royalty Financing Company That Buys Forward Rights to Health System Data Licensing Revenue and Turns Clinical Records Into a Securitizable Asset Clashttps://www.onhealthcare.tech/p/part-ii-royalty-pharma-for-real-worldThoughts on Healthcare Markets & Technologyen2026-07-15T13:23:06+00:00Part II: Royalty Pharma for Real World Data: A Royalty Financing Company That Buys Forward Rights to Health System Data Licensing Revenue & Turns Clinical Records Into a Securitizable Asset Classhttps://www.onhealthcare.tech/p/part-i-royalty-pharma-for-real-worldThoughts on Healthcare Markets & Technologyen2026-07-15T13:19:26+00:00Part I: Royalty Pharma for Real World Data: A Royalty Financing Company That Buys Forward Rights to Health System Data Licensing Revenue & Turns Clinical Records Into a Securitizable Asset Classhttps://www.onhealthcare.tech/p/insuring-the-clawback-why-radv-extrapolation-4dcThoughts on Healthcare Markets & Technologyen2026-07-15T00:37:15+00:00Insuring the Clawback: Why RADV Extrapolation Turned Medicare Advantage Risk Adjustment Into an Unreserved Balance Sheet Liability and the Case for Building a Regulatory Recoupment Insurance Markethttps://www.onhealthcare.tech/p/insuring-the-clawback-why-radv-extrapolationThoughts on Healthcare Markets & Technologyen2026-07-15T00:31:45+00:00Insuring the Clawback: Why RADV Extrapolation Turned MA Risk Adjustment Into an Unreserved Balance Sheet Liability and the Case for Building a Regulatory Recoupment Insurance Market Vehicle